在渐进性上核性麻中发生的状和外状单氨基性干扰
Jing-Hong Ma1, Chong Dong1, Hong-Wen Qiao2,3
1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
概括
与帕金森病 (PD) 相比,F-FP-DTBZ PET在渐进性上核性麻 (PSP) 中显示出不同的VMAT2结合模式. 导致性干扰在PSP中更严重,与姿势不稳定性和认知功能相关.
科学领域:
- 神经成像是一种神经成像.
- 神经学 神经学
- 分子成像学分子成像学
背景情况:
- F-9-fluoropropyldihydrotetrabenazine (F-FP-DTBZ) 定子发射断层扫描 (PET) 是帕金森病 (PD) 的一个验证的生物标志物.
- 关于其在渐进性上核性麻 (PSP) 中有用性的证据有限.
- 膀单胺转运体2 (VMAT2) 是F-FP-DTBZ的目标.
研究的目的:
- 通过使用F-FP-DTBZ PET来评估PSP中的条形和外条形单氨基基干扰.
- 为了比较PSP,PD和健康对照 (HC) 之间的VMAT2结合模式.
- 在PSP患者中将VMAT2结合与临床特征相关联.
主要方法:
- 在58名PSP患者,23名PD患者和17名HC患者身上进行了F-FP-DTBZPET/CT扫描.
- 图像被空间规范化并使用兴趣区域方法进行分析.
- 评估了VMAT2结合在条纹和外条纹区域.
主要成果:
- 在各组的条纹体和黑质体中观察到VMAT2结合的显著差异 (P < 0.001).
- PSP患者比PD患者表现出更严重的尾状VMAT2干扰 (P < 0.001).
- 在PSP患者中,状体VMAT2结合与姿势不稳定相关,海马体结合与认知得分相关.
结论:
- 18F-FP-DTBZ PET突出了PSP,PD和HC之间的显著尾状VMAT2结合差异.
- 纹状体和海马体的VMAT2结合反映了PSP中姿势不稳定性和认知障碍的严重程度.
相关概念视频
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
621
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
621


